Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Gynecol Cancer ; 24(6): 967-72, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24978707

ABSTRACT

Diagnosis of ovarian mass during pregnancy is a rare event. Treatment of ovarian malignancies during pregnancy depends on histology, grade, stage, and gestational weeks. When possible, surgical excision is indicated, and sometimes, fertility-sparing surgery is recommended. Administration of systemic treatment before or after surgery is indicated as in nonpregnant women. Preliminary data suggest that platinum salts and taxanes are safe during pregnancy. Management of ovarian tumors in pregnancy requires a multidisciplinary approach to guarantee an optimal treatment for the mother and the fetus.


Subject(s)
Infertility, Female/prevention & control , Ovarian Neoplasms/surgery , Female , Gynecologic Surgical Procedures , Humans , Infertility, Female/etiology , Pregnancy
2.
Immunotherapy ; 5(7): 733-41, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23829624

ABSTRACT

Monoclonal antibodies (mAbs) are the cornerstone of the treatment of several types of tumors, but their use in pregnant women is not clearly defined. Here, we report and analyze all available data on mAb treatment in pregnant cancer patients. A literature search was performed from 2000 until January 2013 and all articles addressing safety of mAbs during pregnancy were reviewed. We found very few data on the use of bevacizumab in pregnant women. However, owing to its antiangiogenic effects and possible consequences on fetal development, it should be avoided during pregnancy. Trastuzumab administration has been associated with an elevated incidence of oligohydramnios and poor neonatal outcomes, particularly when prescribed after the first trimester for repeated infusions, and therefore it is not recommended. Rituximab does not seem to be teratogenic, but a transient prolonged neutropenia in the newborns was reported, without major infectious consequences in most cases. Few data are available about other mAbs, and hence their use during pregnancy remains discouraged.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Immunotherapy/methods , Pregnancy Complications, Neoplastic/therapy , Animals , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal, Murine-Derived/adverse effects , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Bevacizumab , Female , Fetal Development/drug effects , Humans , Molecular Targeted Therapy , Oligohydramnios/etiology , Pregnancy , Pregnancy Complications, Neoplastic/immunology , Risk Assessment , Rituximab , Trastuzumab
3.
Breast ; 22(5): 657-60, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23871328

ABSTRACT

BACKGROUND: Breast reconstruction after mastectomy is currently considered an essential component in managing breast cancer patients, particularly those diagnosed at a young age. However, no studies have been published on the feasibility of immediate breast reconstruction in patients diagnosed and operated during the course of gestation. METHOD: We retrospectively identified all breast cancer patients who were subjected to mastectomy and immediate breast reconstruction during pregnancy at the European Institute of Oncology between 2002 and 2012. Patient demographics, gestational age at surgery, tumor stage, adjuvant treatment, details of the surgical procedures, surgical outcomes and fetal outcomes were analyzed. RESULTS: A total of 78 patients with breast cancer diagnosed during pregnancy were subjected to a surgical procedure during the course of gestation. Twenty-two patients had mastectomy; of whom 13 were subjected to immediate breast reconstruction. Twelve out of 13 patients had a two-stage procedure with tissue expander insertion. Median gestational age at surgery was 16 weeks. No major surgical complications were encountered. Only one patient elected to have an abortion, otherwise, no spontaneous abortions or pregnancy complications were reported. Median gestational age at delivery was 35 weeks (range: 32-40 weeks). No major congenital malformations were reported. At a median follow-up of 32 months, all patients are alive with no long-term surgical complications. CONCLUSIONS: This is the first study of immediate breast reconstruction in pregnant breast cancer patients. Tissue expander insertion appears to ensure a short operative time, and does not seem to be associated with considerable morbidity to the patient or the fetus. Hence, it could be considered in the multidisciplinary management of women diagnosed with breast cancer during pregnancy.


Subject(s)
Breast Neoplasms/surgery , Mammaplasty/methods , Pregnancy Complications, Neoplastic/surgery , Adult , Female , Gestational Age , Humans , Live Birth , Mammaplasty/instrumentation , Mastectomy , Pregnancy , Retrospective Studies , Time Factors , Tissue Expansion Devices
4.
Cancer Treat Rev ; 39(3): 207-11, 2013 May.
Article in English | MEDLINE | ID: mdl-23199900

ABSTRACT

An increasing number of women are diagnosed with cancer during pregnancy and lactation. Women are usually advised to interrupt breastfeeding during systemic anticancer treatment for fear of serious adverse effects to the nursed infant. However, the issue is poorly addressed in the literature and very few studies have evaluated the safety of breastfeeding during or after cytotoxic drugs or target agents administration. In this review we will analyze the available evidence that addresses the issue of anticancer drugs, targeted agents, antiemetics and growth-factors excretion in human milk. This could serve as a unique resource that may aid physicians in the management of breastfeeding cancer patients interested in maintaining lactation during treatment.


Subject(s)
Antiemetics/pharmacokinetics , Antineoplastic Agents/pharmacokinetics , Breast Feeding , Breast Neoplasms/metabolism , Intercellular Signaling Peptides and Proteins/pharmacokinetics , Lactation/metabolism , Milk, Human/metabolism , Pregnancy Complications, Neoplastic/metabolism , Antiemetics/adverse effects , Antineoplastic Agents/adverse effects , Breast Neoplasms/drug therapy , Drug-Related Side Effects and Adverse Reactions/chemically induced , Female , Humans , Infant, Newborn , Intercellular Signaling Peptides and Proteins/adverse effects , Male , Pregnancy , Pregnancy Complications, Neoplastic/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...